Online supplement. Online supplement containing additional details regarding COPD medications, treatment compliance and adverse events. (DOC 30Â kb
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documen...
Fig S1. Kaplan–Meier curves and Cox proportional hazard model on time to first moderate-to-severe CO...
Patient demographics and clinical characteristics for COPD patients aged over 40 years old. (DOCX 14...
List of institutions and Independent Ethics Committees/Institutional Review Boards for Study DB21161...
Results from the analyses of FVC other endpoints (selected) (ITT population). (DOC 43Â kb
Proportion of patients achieving an increase FEV1 ≥ 0.100 L above baseline at various times post-dos...
COPD-related medications. COPD-related treatments identified by pharmacy claims in the baseline peri...
Study design Figure. Abbreviations: BDI, Baseline Dyspnoea Index; CAT, COPD Assessment Test; FP/SAL,...
Results from the analyses reporting proportions of patients achieving lung function improvements for...
Cohort counts by month of UMEC/VI initiation (Nâ=â2200). Additional figure illustrating the numb...
MSM sensitivity analyses for COPD-related medical costs. Sensitivity analyses conducted to test the ...
Independent variables in treatment selection weighting models for cost analyses. Description of inde...
Improvement in COPD disease factors in the model at time = 0. Description of the improvements in COP...
COPD refresher presentation. The training presentation used to refresh participating pharmacistsâ ...
Online supplement - Table S1. PtCO2 change âĽ4 mmHg according to randomised treatment. Table S2. S...
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documen...
Fig S1. Kaplan–Meier curves and Cox proportional hazard model on time to first moderate-to-severe CO...
Patient demographics and clinical characteristics for COPD patients aged over 40 years old. (DOCX 14...
List of institutions and Independent Ethics Committees/Institutional Review Boards for Study DB21161...
Results from the analyses of FVC other endpoints (selected) (ITT population). (DOC 43Â kb
Proportion of patients achieving an increase FEV1 ≥ 0.100 L above baseline at various times post-dos...
COPD-related medications. COPD-related treatments identified by pharmacy claims in the baseline peri...
Study design Figure. Abbreviations: BDI, Baseline Dyspnoea Index; CAT, COPD Assessment Test; FP/SAL,...
Results from the analyses reporting proportions of patients achieving lung function improvements for...
Cohort counts by month of UMEC/VI initiation (Nâ=â2200). Additional figure illustrating the numb...
MSM sensitivity analyses for COPD-related medical costs. Sensitivity analyses conducted to test the ...
Independent variables in treatment selection weighting models for cost analyses. Description of inde...
Improvement in COPD disease factors in the model at time = 0. Description of the improvements in COP...
COPD refresher presentation. The training presentation used to refresh participating pharmacistsâ ...
Online supplement - Table S1. PtCO2 change âĽ4 mmHg according to randomised treatment. Table S2. S...
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documen...
Fig S1. Kaplan–Meier curves and Cox proportional hazard model on time to first moderate-to-severe CO...
Patient demographics and clinical characteristics for COPD patients aged over 40 years old. (DOCX 14...
DOI
Add to ORKG